Abstract: New designs, methods and processes are described that in which laminated devices and configured in a style named the “ortho” style. To form a device in the ortho style, plates or sheets are machined to have apertures and then stacked together such that the apertures connect and fluid can flow through the device in a direction that is substantially parallel to the direction of sheet thickness. Various laminated devices and processes using them are also described. For example, devices in which non-rectangular microchannels conform around reaction chambers or other bodies that need to be heated or cooled, are described. Features that separate or trip boundary layer and enhance heat transfer are also described.

Abstract: Process and apparatus for the (co) polymerization of styrene. The process is carried out by employing a liquid polymerization reaction mixture that includes styrene, in a mechanically stirred reactor in the form of a vessel comprising a side wall having the shape of a cylinder of revolution with a vertical axis (A), a bottom head and a top head that are joined to the side wall. The vessel is provided with a mechanical stirring device comprising (i) a central shaft of vertical axis coincident with the axis (A), connected to a drive system comprising a motor for rotating the central shaft, (ii) at least one baffle attached to the vessel. The baffle is away from the side wall of the vessel and takes the form of a cylinder of vertical axis and of rhomboidal cross section.

Abstract: A reformer having a combustion unit including a combustion part to burn air and fuel, a combustion gas distributor to distribute the burned combustion gas, and first and second combustion gas passages to guide the distributed combustion gas into an outlet. A fuel-converting catalytic reaction unit includes two reforming reaction parts preparing a reforming reaction reformate, each having a reforming catalyst to reform feed and water supplied from a feed/water inlet, and a water gas shift reaction part preparing a water gas shift reformate, between the two reforming reaction parts to decrease a concentration of carbon monoxide in the reforming reacting reformate. The two units are structured as six cylindrical pipes to realize optimal heat exchange efficiency, and preferential oxidation reactor is provided between first air fuel preheating passages in the combustion part to decrease the concentration of carbon monoxide in the water gas shift reformate to a predetermined level or lower.

Abstract: Apparatus for producing nano-particles includes a furnace defining a vapor region therein. A precipitation conduit having an inlet end and an outlet end is positioned with respect to the furnace so that the inlet end is open to the vapor region. A quench fluid supply apparatus supplies quench fluid in a gas state and quench fluid in a liquid state. A quench fluid port positioned within the precipitation conduit is fluidically connected to the quench fluid supply apparatus so that an inlet to the quench fluid port receives quench fluid in the gas state and quench fluid in the liquid state. The quench fluid port provides a quench fluid stream to the precipitation conduit to precipitate nano-particles within the precipitation conduit. A product collection apparatus connected to the outlet end of the precipitation conduit collects nano-particles produced within the precipitation conduit.

Abstract: A coke removal system removes coke deposits from the walls of a high temperature passage in which hydrocarbon fuel is present. The system includes a carbon-steam gasification catalyst and a water source. The carbon-steam gasification catalyst is applied to the walls of the high temperature passage. The water reacts with the coke deposits on the walls of the high temperature passage to remove the coke deposits from the walls of the high temperature passage by carbon-steam gasification in the presence of the carbon-steam gasification catalyst.

Abstract: The present invention provides a fuel treatment device which can realize easy separation and collection of a catalyst contained in the device. In a fuel treatment device (21) of the present invention a fuel gas is supplied to a catalyst, which fills a catalyst filling space (24) surrounded by a cylindrical inner circumferential wall and a cylindrical outer circumferential wall, to produce a reformed gas. The fuel treatment device (21) has a removal section indicator indicating a catalyst removal section (29) on the outer circumferential surface of the outer circumferential wall of the cylindrical catalyst filling space (24) and an opening formation assister assisting the formation of a catalyst removal opening for removing the catalyst.

Abstract: A system for chemically disposing energetic material enclosed in assembled devices includes a porous basket. The porous basket forms an enclosed chamber for receiving the assembled devices. Further, the basket is supported by a rotatable basket arm that is, in turn, connected to a lifting arm. In addition to these structures, the system includes a tank that holds a hydrolysis solution. The tank is positioned to allow the lifting arm to submerge the basket into the solution. After submersion, the basket arm rotates the basket in the solution to flow the hydrolysis solution into contact with the assembled devices therein. As a result, the assembled devices react with the solution so that the solution penetrates the assembled devices, allowing the solution to contact and react with the energetic material to render the energetic material non-energetic.

Abstract: This deer lure with scent dispenser has an outer casing with an interior plenum, a lower end and an upper end, with air inlet holes adjacent the lower end, a base adapted to fit into the lower end and extend into the plenum, and a scent dispenser assembly with a reservoir adapted to fit into the upper end with its exterior extending into the plenum. The base is adapted to serve as a pedestal for a candle and to hold the candle above the air inlet holes. The base also allows air for the candle to enter the plenum from the air inlet holes and reach a flame of the candle. The reservoir has an interior in communication with air exterior to the casing for holding a volatile scented liquid, and the invention allows hot gases produced by the candle to escape from the plenum into air exterior to the plenum around and/or through the reservoir, volatilizing the scented liquid in the reservoir.

Abstract: There is disclosed a hydrothermally stable microporous crystalline material comprising a molecular sieve or zeolite having an 8-ring pore opening structure, such as SAPO-34 or aluminosilicate zeolite, able to retain a specific percentage of its surface area and micropore volume after treatment with heat and moisture, such as at least 80% of its surface area and micropore volume after exposure to temperatures of up to 900° C. in the presence of up to 10 volume percent water vapor for a time ranging from 1 to 16 hours. Methods of using the disclosed crystalline material, such as in the SCR of NOx in exhaust gas are also disclosed, as are methods of making such materials.

Abstract: The present invention provides for methods of purifying silicon, methods for obtaining purified silicon, as well as methods for obtaining purified silicon crystals, purified granulized silicon and/or purified silicon ingots.

Abstract: A method for making a white synthetic carbide lime filler composition of calcium hydroxide and calcium carbonate, wherein the calcium carbonate is in the form of surface carbonation on the calcium hydroxide. The method can include calcining calcium carbonate, hydrating the calcined material under controlled conditions which maintain a low moisture content and fracture the hydrated material into small particles of calcium hydroxide, carbonating the small calcium hydroxide particles to create the surface carbonation of calcium carbonate, and classifying the carbonated synthetic carbide lime particles to separate off oversized particles. The method can use a combined classifying and carbonating process, and a modified classifying vessel can be provided to carry out the combined process.

Abstract: A process for gasification is provided for a non-catalytic, two-stage gasification process for gasification of a carbonaceous material. The reactor system generally comprises combustion in a first reaction zone and combustion in a second reaction zone.

Abstract: An assembly comprising carbon foam and high density carbon foam is described. In some embodiments, such an assembly may be a composite or composite assembly. One or more pieces of carbon foam and high density carbon foam may comprise the assembly. The assembly may comprise other materials in addition to the carbon foam and high density carbon foam. One or more of any given type of other material may be incorporated into the composite. Additionally, a given other material may be incorporated in more than one volume or location on or in the assembly. The other materials may provide for bonding of the elements of the assembly together, strengthening of the assembly, increased assembly oxidation and weathering resistance, modification of the electrical, thermal, or fluid transport properties of the assembly, and any of a number of other purposes.

Abstract: The present invention relates to a method for producing colorless, single-crystal diamonds at a rapid growth rate. The method for diamond production includes controlling temperature of a growth surface of the diamond such that all temperature gradients across the growth surface of the diamond are less than about 20° C., and growing single-crystal diamond by microwave plasma chemical vapor deposition on the growth surface of a diamond at a growth temperature in a deposition chamber having an atmosphere, wherein the atmosphere comprises from about 8% to about 20% CH4 per unit of H2 and from about 5 to about 25% O2 per unit of CH4. The method of the invention can produce diamonds larger than 10 carats. Growth rates using the method of the invention can be greater than 50 ?m/hour.

Abstract: Separation of carbon nanotubes or fullerenes according to diameter through non-covalent pi-pi interaction with molecular clips is provided. Molecular clips are prepared by Diels-Alder reaction of polyacenes with a variety of dienophiles. The pi-pi complexes of carbon nanotubes with molecular clips are also used for selective placement of carbon nanotubes and fullerenes on substrates.

Abstract: This disclosure relates to a crystalline MCM-22 family molecular sieve having a platelet aggregates morphology wherein greater than 50 wt % of the molecular sieve having a crystal diameter greater than 1 ?m as measured by the SEM. The crystalline MCM-22 family molecular sieve of this disclosure, wherein the platelet aggregates morphology is rosette habit morphology, or multiple layer plate's morphology.

Abstract: This invention relates to novel 15O-labeled monosaccharide useful for positron emission tomography (PET) and producing method thereof.

Abstract: A polycation capable of forming a complex with a nucleic acid for carriage thereof. The polycation comprising at least one cyclic compound having a cavity. A polymer backbone is threaded into the cavity of the cyclic compound. A pair of bulky moieties cap the terminals of the polymer backbone to inhibit dethreading of the cyclic compound from the polymer backbone. In use, the net positive charge of said polycation enables a complex to form with nucleic acid.

Abstract: The present application relates to the induced remineralization of human tooth enamel and in particular to the building up of apatite on tooth material.

Abstract: The invention concerns a composition comprising, in a physiologically acceptable medium, at least a liquid fatty phase comprising at least a volatile organic solvent and at least an aqueous phase. The invention is characterised in that the aqueous phase contains a micro-dispersion of wax particles. The composition results, after being applied on keratinous fibres, in a water-resistant film and provides good curved shape to the keratinous fibres. The invention is applicable to mascara.

Abstract: The present invention provides cosmetic compositions and products that contain camel milk or components thereof, wherein the milk or components may be pre-treated by a physical or biochemical process. The invention further relates to a process for preparing cosmetic compositions containing camel milk or components thereof.

Abstract: The invention concerns a polymer comprising water soluble units and LCST units consisting of ethylene oxide and propylene oxide random copolymers, or one of its salts. The invention also concerns an aqueous composition in particular thickened, even gelled, comprising such a polymer or one of its salts and an aqueous phase.

Abstract: Crosslinkable compositions are provided that readily crosslink in situ to provide biocompatible, nonimmunogenic crosslinked materials that may be used as adhesive compositions. The compositions comprise collagen and a plurality of crosslinkable components having reactive functional groups thereon, with the functional groups selected so as to enable inter-reaction between the components, i.e., crosslinking. Methods for preparing and using the compositions are also provided. Exemplary uses include tissue augmentation, biologically active agent delivery, bioadhesion, prevention of adhesions following surgery or injury, and coating of surgically acceptable patches and solid implants, the latter including sutures.

Abstract: Provided are crosslinked polymer compositions that include a first synthetic polymer containing multiple nucleophilic groups covalently bound to a second synthetic polymer containing multiple electrophilic groups. The first synthetic polymer is preferably a synthetic polypeptide or a polyethylene glycol that has been modified to contain multiple nucleophilic groups, such as primary amino (—NH2) or thiol (—SH) groups. The second synthetic polymer may be a hydrophilic or hydrophobic synthetic polymer, which contains or has been derivatized to contain, two or more electrophilic groups, such as succinimidyl groups. The compositions may further include other components, such as naturally occurring polysaccharides or proteins (such as glycosaminoglycans or collagen) and/or biologically active agents.

Abstract: Purified genes encoding cytokine from a mammal, reagents related thereto including purified proteins, specific antibodies, and nucleic acids encoding this molecule are provided. Methods of using said reagents and diagnostic kits are also provided.

Abstract: Bacterial delivery systems with improved transgene expression are provided. The recombinant bacterial delivery systems deliver transgenes of interest and suppressors of the eukaryotic Type I interferon response to eukaryotic cells. Suppression of the eukaryotic Type I interferon response allows improved expression of the encoded transgene.

Abstract: The present invention relates to the use of compositions comprising receptor ligands obtainable by a process comprising fermenting a food material, comprising animal milk or vegetable proteins, with lactic acid bacteria to obtain a fermented food or feed material that comprises ligands of specific adrenoreceptors and/or serotonin receptors. The fermented food or feed material is useful e.g. for reducing and/or stabilizing heart rate in a mammal. It may furthermore be used for treatment and/or relief of erectile dysfunctions and for treatment and/or relief of benign prostate hypertrophy (BPH), in a mammal.

Abstract: The present invention is directed to compositions of fetal hematopoietic stem and progenitor cells and stromal (mesencymal) cells derived from second trimester (16-20 weeks gestation) miscarriages, that are isolated, processed and cryopreserved, and the therapeutic uses of such stem and progenitor cells upon application. Such compositions may be useful for hematopoietic reconstitution and/or replacement in patients with various diseases and metabolic disorders. The invention also relates to methods for collecting, isolating, processing and cryopreserving of the fetal stem and progenitor cells of the invention. Importantly, the invention meets an urgent need in regenerative medicine while at the same time ensures utility of the product compositions because it utilizes fetal materials from second trimester (16-20 weeks of gestation) spontaneously lost pregnancies which are free of moral or ethical burdens.

Abstract: The invention provides methods to for treating a an obstructed biological conduit that include administering to the conduit an agent that can degrade extracellular matrix of obstructing tissue. Particular methods include delivery of an enzyme or a mixture of several enzymes to the area or region of obstruction wherein the enzyme(s) have the capability to degrade extracellular matrix components within the obstruction thereby restoring the normal flow of transported fluid through the conduit. The invention also includes prophylactically dilating a section of conduit to minimize the risk of obstruction formation.

Abstract: Human anti-human IL-21 monoclonal antibodies and the hybridomas that produce them are presented. Certain of these antibodies have the ability to bind native human IL-21, a mutant recombinant IL-21 protein and/or peptide regions of human IL-21. These human anti-IL-21 antibodies are useful in therapeutic treatment of autoimmune and inflammatory diseases, particularly diseases mediated by T follicular helper cells, B cells TH cells or TH17 cells.

Abstract: A method for reducing gastrointestinal inflammation, enhancing growth, or improving feed efficiency in a human or non-human animal is disclosed. The method involves administering to the animal an agent that can reduce the formation of the signal transduction complex of endotoxin, TLR4 and CD14 on the cellular surface of a cell in the gastrointestinal tract of the animal. In a preferred embodiment, an antibody against the extracellular domain of TLR4 or CD14 is used to reduce the formation of the complex. A composition that contains the antibody and an ingestible carrier is also disclosed. Further disclosed is a method for producing a peptide for enhancing growth, improving feed efficiency, or both in a human or non-human animal.

Abstract: The present invention relates to cancer therapies using an antibody that binds to mortalin 2 and a functional nucleic acid. Mortalin expression was found to be upregulated in immortalized cells and tumor tissues. Immortalized human cells highly expressing mortalin showed anchorage-independent growth. When the K antibody, which is a specific anti-mortalin antibody, was injected into a tumor of a nude mouse, tumor growth was suppressed or the tumor shrank compared with the case of a control. In accordance with the present invention, the use of a specific anti-mortalin antibody (K antibody) for tumor therapies and the use of such antibody as a carrier molecule for transportation of immunotoxicin and the like into cells are provided. It has been shown that mortalin can be a target for cancer therapies. In accordance with the present invention, a novel and effective anticancer agent is provided. In addition, an anti-mortalin antibody that is internalized by cells is developed.

Abstract: The invention provides novel methods of administering anti-CD3 antibodies, e.g., via oral or mucosal delivery. The invention also provides methods of treating, preventing, or delaying the onset of autoimmune disorders by oral or mucosal administration of anti-CD3 antibodies. Finally, the invention provides compositions including anti-CD3 antibodies, suitable for oral or mucosal administration.

Abstract: Human antibodies, preferably recombinant human antibodies, that specifically bind to human interleukin-12 (hIL-12 ) are disclosed. Preferred antibodies have high affinity for hIL-12 and neutralize hIL-12 activity in vitro and in vivo. An antibody of the invention can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, of the invention are useful for detecting hIL-12 and for inhibiting hIL-12 activity, e.g., in a human subject suffering from a disorder in which hIL-12 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies of the invention, and methods of synthesizing the recombinant human antibodies, are also encompassed by the invention.

Abstract: To provide an antibody against FGF23 and a pharmaceutical composition such as a preventive or therapeutic agent which can prevent or treat by suppressing an action of FGF23 by using the antibody. An antibody or its functional fragment against human FGF23 produced by hybridoma C10 (Accession No. FERM BP-10772).

Abstract: The present invention relates to antigens, more particularly antigens of Streptococcus pyogenes (also called group A streptococcus (GAS)) bacterial pathogen which are useful as vaccine component for prophylaxis, therapy and/or diagnostic.

Abstract: Antigen specific immune tolerance is induced in a mammalian host by administration of a toleragen in combination with a regimen of immunosuppression. The methods optionally include a preceding conditioning period, where immunosuppressive agents are administered in the absence of the toleragen. After the tolerizing regimen, the host is withdrawn from the suppressive agents, but is able to maintain specific immune tolerance to the immunogenic epitopes present on the toleragen. Optimally, the toleragen will have high uptake properties that allow uptake in vivo at low concentrations in a wide variety of tolerizing cell types.

Abstract: A novel substance that has the physiological activity of the aglycone of isoflavones and the physiological activity of the culture of the basidiomycetes with the physiological activities being synergistically enhanced, obtained by cultivating a basidiomycetes having a ?-glucosidase activity in a medium containing an isoflavone, a method for producing it, and food, feedstuff and medicine containing it. The substance of the invention is improved in the physiological effect of the aglycone of isoflavones and the physiological effect of the culture of the basidiomycetes, and is not only useful as an anti-tumor agent but also is useful for therapy and/or prevention of osteoporosis and also as an immune enhancement agent.

Abstract: This invention relates to the stabilization of a bacterial ADP-ribosylating exotoxin class protein (bARE), a method for analysing a bARE class protein, a method for the stabilization of the bARE class bacterial protein, compositions comprising a stabilized bARE protein, compositions comprising a substantially integral bARE class protein and immunogenic composition formulations incorporating same.

Abstract: This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A Streptococcus (GAS) serotypes. At least some of the synthetic peptides can be recognized by M type-specific antibodies and are capable of eliciting functional opsonic antibodies and/or anti-attachment antibodies without eliciting tissue cross-reactive antibodies. In another aspect, it relates to compositions or vaccines comprising these synthetic serotype-specific peptides, including polypeptides and proteins. The invention may also be isolated antibodies which are raised in response to the peptides, compositions or vaccines. The invention further relates to kits for using the peptides, compositions, or antibodies.

Abstract: The present invention relates to the use of polypeptides related to a Bacillus licheniformis polypeptide (amino acids 1-85 of SEQ ID NO: 2) as antimicrobial agents, for example in pharmaceutical applications, including veterinary applications, as well as for preservation, cleaning and disinfection of various surfaces, objects and substances. The polypeptides may in particular be used to treat textiles or laundry, e.g., in detergents, for reducing microbes on textile or laundry, and/or for odor reduction. The invention also relates to use of Bacillus strains producing these polypeptides as antimicrobial agents. Examples of microorganism inhibited by Lento are Gram positive bacterial strains, such as Bacillus cereus, and various species of Corynebacterium, Enterococcus, Micrococcus, Streptococcus, and Staphylococcus.

Abstract: The present invention relates to a strain of M. bovis BCG or M. microti, wherein said strain has integrated part or all of the RD1 region responsible for enhanced immunogenicity of the tubercle bacilli, especially the ESAT-6 and CFP-10 genes. These strains will be referred as the M bovis BCG::RDI or M. microti::RD1 strains and are useful as a new improved vaccine for preventing tuberculosis and as a therapeutical product enhancing the stimulation of the immune system for the treatment of bladder cancer. These strains are also useful for the expression and presentation of heterologous antigens and molecule that are of therapeutic or prophylactic interest.

Abstract: The invention relates to the topical application of substituted thiazolyl amides in the treatment of herpes infections in humans, to preparations suitable for the topical application and to the production thereof.

Abstract: The invention describes novel nitrosated nonsteroidal antiinflammatory drugs (NSAIDs) and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated NSAID, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one nitrosated NSAID, and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one nitrosated NSAID, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent.

Abstract: Solid and liquid pesticidal concentrate and spray compositions are described which exhibit enhanced efficacy due to the addition thereto of a compound which increases EPSPS enzyme inhibition by the pesticide, cell membrane permeability, or expression of hydroxyproline-rich glycoproteins.

Abstract: A water dispersible granule formulation prepared by pulverized a part of active ingredients into fine particles under wet milling and pulverized another part of the active ingredients into coarse particles under dry milling, then kneading the both active ingredients for the granulation, and a process for producing the water dispersible granule formulation are disclosed. The water dispersible granule formulation according to the present invention is applicable for production of a water dispersible granule formulation comprising an active ingredient which is easily decomposed owing to environmental conditions and allows to provide the water dispersible granule formulation provided with enhanced initial and residual biological activities.

Abstract: A delivery device that allows for the sustained release of an agent, particularly useful for the sustained release of a therapeutic agent to limited access regions, such as the posterior chamber of the eye and inner ear. The delivery device is minimally invasive, refillable and may be easily fixed to the treatment area. The delivery device includes a hollow body with an inlet port at its proximal end for insertion of the agent, a reservoir for holding the agent and a delivery mechanism for the sustained delivery of the agent from the reservoir to the patient.

Abstract: The invention relates to an drug delivery device and a method for delivering multiple drugs over a prolonged period of time. The drug delivery device has two or more unitary segments comprising a drug-permeable polymeric substance, wherein at least one of the segments further comprises a pharmaceutically active agent. The invention also relates to a method for the treatment of a benign ovarian secretory disorder in a female mammal, a method of contraception, and a method of relieving the symptoms associated with menopausal, perimenopausal and post-menopausal periods in a woman.

Abstract: A patch comprising a backing layer and an adhesive layer disposed on the backing layer and compounded with an adhesive agent and oxybutynin and/or a pharmaceutically acceptable salt thereof, wherein the adhesive agent comprises an acrylic polymer substantially free of both carboxyl group and hydroxyl group and a rubber polymer, in which weight ratio of content of the acrylic polymer to content of the rubber polymer is from 1:4 to 1:19.

Abstract: The present invention provides dynamic charge state cationic polymers that are useful for delivery of anionic molecules. The dynamic charge state cationic polymers are designed to have cationic charge densities that decrease by removal of removable functional groups from the polymers. The present invention also provides interpolyelectrolyte complexes containing the polymers complexed to a polyanion. Methods for using the interpolyelectrolyte complexes to deliver anionic compounds are also provided.